Conference Calendar - The 33rd International Papillomavirus Conference

Times are stated in CEST (GMT + 2 / UTC + 2)
Every effort has been made to convert the IPVC 2020 scientific program into a fully virtual program. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive program on the virtual conference platform. Please note that some presenters were not able to pre-record their presentations, therefore there are still some sessions with missing presentations.

To view the pre-conference workshops, you need to register for them separately. Please contact: reg_ipvc20@kenes.com
You will then receive an email with instructions on how to login to the workshops’ platform.

Displaying One Session

View

Public Health Oral Session

00920 - Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening (ID 40)

Session Type

Public Health Oral Session

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY: EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT \u003Csmall\u003E(ID 1069)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1069,"presentation":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY: EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT \u003Csmall\u003E(ID 1069)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Clare Gilham (United Kingdom)","photo":""},"playlist":[{"name":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/E99BB056.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.vtt"}]},{"name":"EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY \u003Csmall\u003E(ID 1350)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1350,"presentation":"EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY \u003Csmall\u003E(ID 1350)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Nicolas Wentzensen (United States of America)","photo":""},"playlist":[{"name":"Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMP","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/26C69DD6.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.vtt"}]},{"name":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TENNESSEE, UNITED STATES WOMEN DURING 2006-2017 \u003Csmall\u003E(ID 863)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":863,"presentation":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TENNESSEE, UNITED STATES WOMEN DURING 2006-2017 \u003Csmall\u003E(ID 863)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Manideepthi Pemmaraju (United States of America)","photo":""},"playlist":[{"name":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TEN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/22F65966.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.vtt"}]},{"name":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA \u003Csmall\u003E(ID 855)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":855,"presentation":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA \u003Csmall\u003E(ID 855)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Raul H. Murillo (Colombia)","photo":""},"playlist":[{"name":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/855.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/855.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/DD372A01.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/855.vtt"}]},{"name":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIFIC CANCER RISK \u003Csmall\u003E(ID 1043)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1043,"presentation":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIFIC CANCER RISK \u003Csmall\u003E(ID 1043)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Yanzi Xiao (United States of America)","photo":""},"playlist":[{"name":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIF","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/E9EEB14D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.vtt"}]},{"name":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL \u003Csmall\u003E(ID 969)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":969,"presentation":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL \u003Csmall\u003E(ID 969)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Lovedeep Gondara (Canada)","photo":""},"playlist":[{"name":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/BDC5B9B7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.vtt"}]},{"name":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING \u003Csmall\u003E(ID 869)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":869,"presentation":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING \u003Csmall\u003E(ID 869)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Didem Egemen (United States of America)","photo":""},"playlist":[{"name":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/A57789A2.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.vtt"}]},{"name":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA \u003Csmall\u003E(ID 724)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":724,"presentation":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA \u003Csmall\u003E(ID 724)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Adam Keane (Australia)","photo":""},"playlist":[{"name":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/C6B3599F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.vtt"}]}]

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY: EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT (ID 1069)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

12:20 - 12:32

Presenter

Clare Gilham (United Kingdom)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

RANDOMIZED IMPLEMENTATION OF HPV-SCREENING IN NORWAY: REAL-WORLD DATA (ID 1343)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

12:32 - 12:44

Presenter

Ameli Tropé (Norway)

Authors

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY (ID 1350)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

12:44 - 12:56

Presenter

Nicolas Wentzensen (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TENNESSEE, UNITED STATES WOMEN DURING 2006-2017 (ID 863)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

12:56 - 13:08

Presenter

Manideepthi Pemmaraju (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

CANCER CASES IDENTIFIED IN A RANDOMIZED IMPLEMENTATION OF HVP-SCREENING IN THE NORWEGIAN CERVICAL CANCER SCREENING PROGRAMME (ID 1218)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

13:08 - 13:20

Presenter

Birgit Engesæter (Norway)

Authors

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA (ID 855)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

13:20 - 13:32

Presenter

Raul H. Murillo (Colombia)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIFIC CANCER RISK (ID 1043)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

13:32 - 13:44

Presenter

Yanzi Xiao (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL (ID 969)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

13:44 - 13:56

Presenter

Lovedeep Gondara (Canada)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING (ID 869)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

13:56 - 14:08

Presenter

Didem Egemen (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA (ID 724)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

14:08 - 14:20

Presenter

Adam Keane (Australia)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening Hall E

Online Chat Q&A for this session is called: PUBLIC HEALTH ORAL SESSION 13: SCREENING V. EVALUATION AND IMPACT OF CERVICAL CANCER SCREENING. You can join the online chat Q&A and discussions for this session by going back to the Lobby and entering the Networking Lounge. Speakers are encouraged to be online in the chat room at the time this session is stated to end. All times are in CEST. (ID 1811)

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening

Lecture Time

14:20 - 14:20